Inventor · disambiguated record
Stephen W. Fesik
Also filed as: FESIK STEPHEN W
30 granted patents·20 pending applications·550 citations·filing 1995–2024
96Inventor score
Files withUNIV VANDERBILT19ABBOTT LAB14BOEHRINGER INGELHEIM INTL GMBH CORP5BOEHRINGER INGELHEIM INT4FESIK STEPHEN W1
Top patents by PatentIndex Score
50 records- 0198US6720338B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2001·Granted Apr 13, 2004·98 cites·9 claims
- 0297US7754886B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2009·Granted Jul 13, 2010·34 cites·18 claims
- 0397US7504512B2N-acylsulfonamide apoptosis promotersABBOTT LAB·Filed 2004·Granted Mar 17, 2009·58 cites·18 claims
- 0488US5698401AUse of nuclear magnetic resonance to identify ligands to target biomoleculesABBOTT LAB·Filed 1995·Granted Dec 16, 1997·82 cites·3 claims
- 0587US10160763B2WDR5 inhibitors and modulatorsUNIV VANDERBILT·Filed 2017·Granted Dec 25, 2018·5 cites·21 claims
- 0686US5804390AUse of nuclear magnetic resonance to identify ligands to target biomoleculesABBOTT LAB·Filed 1997·Granted Sep 8, 1998·70 cites·4 claims
- 0784US10844044B2WDR5 inhibitors and modulatorsUNIV VANDERBILT·Filed 2019·Granted Nov 24, 2020·4 cites·20 claims
- 0884US10501466B2WDR5 inhibitors and modulatorsUNIV VANDERBILT·Filed 2018·Granted Dec 10, 2019·3 cites·20 claims
- 0983US5891643AUse of nuclear magnetic resonance to design ligands to target biomoleculesABBOTT LAB·Filed 1995·Granted Apr 6, 1999·67 cites·8 claims
- 1080US10533010B2Substituted indole Mcl-1 inhibitorsUNIV VANDERBILT·Filed 2015·Granted Jan 14, 2020·3 cites·15 claims
- 1178US10807959B2WDR5-MLL1 inhibitors and modulatorsUNIV VANDERBILT·Filed 2019·Granted Oct 20, 2020·2 cites·18 claims
- 1277US6897337B2Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors thereforABBOTT LAB·Filed 2002·Granted May 24, 2005·6 cites·7 claims
- 1375US12144816B2Substituted indole Mcl-1 inhibitorsUNIV VANDERBILT·Filed 2022·Granted Nov 19, 2024·0 cites·16 claims
- 1475US6043024AUse of one-dimensional nuclear magnetic resonance to identify ligands to target biomoleculesABBOTT LAB·Filed 1997·Granted Mar 28, 2000·38 cites·17 claims
- 1575US5989827AUse of nuclear magnetic resonance to design ligands to target biomoleculesABBOTT LAB·Filed 1996·Granted Nov 23, 1999·44 cites·8 claims
- 1674US11596639B2Substituted indole Mcl-1 inhibitorsUNIV VANDERBILT·Filed 2017·Granted Mar 7, 2023·1 cites·20 claims
- 1773US12195472B2Substituted indole Mcl-1 inhibitorsUNIV VANDERBILT·Filed 2021·Granted Jan 14, 2025·0 cites·17 claims
- 1872US11999716B2WDR5 inhibitors and modulatorsUNIV VANDERBILT·Filed 2019·Granted Jun 4, 2024·1 cites·12 claims
- 1967US11208415B2Substituted indole Mcl-1 inhibitorsUNIV VANDERBILT·Filed 2019·Granted Dec 28, 2021·0 cites·17 claims
- 2066US5665777ABiphenyl hydroxamate inhibitors of matrix metalloproteinasesABBOTT LAB·Filed 1995·Granted Sep 9, 1997·24 cites·14 claims
- 2165US10005728B2Substituted indole Mcl-1 inhibitorsUNIV VANDERBILT·Filed 2014·Granted Jun 26, 2018·0 cites·25 claims
- 2265US6288261B1Inhibitors of matrix metalloproteinasesABBOTT LAB·Filed 1999·Granted Sep 11, 2001·10 cites·14 claims
- 2362US12060367B2Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancerBOEHRINGER INGELHEIM INT·Filed 2023·Granted Aug 13, 2024·0 cites·49 claims
- 2462US2025002504A1Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancerBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 2561US10954193B2Substituted indole Mcl-1 inhibitorsUNIV VANDERBILT·Filed 2018·Granted Mar 23, 2021·0 cites·19 claims
- 2661US2025019385A1Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancerBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 2756US10844032B2Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitorsUNIV VANDERBILT·Filed 2018·Granted Nov 24, 2020·0 cites·20 claims
- 2856US10093640B2Substituted benzofuran, benzothiophene and indole MCL-1 inhibitorsUNIV VANDERBILT·Filed 2013·Granted Oct 9, 2018·0 cites·21 claims
- 2956US2023227470A1Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancerBOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 3055US2025313553A1Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancerBOEHRINGER INGELHEIM INTL GMBH CORP·Filed 2022·Application pending·0 cites
- 3154US2025296940A1Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancerBOEHRINGER INGELHEIM INTL GMBH CORP·Filed 2022·Application pending·0 cites
- 3254US2025129095A1Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancerBOEHRINGER INGELHEIM INTL GMBH CORP·Filed 2022·Application pending·0 cites
- 3354US2006031945A1Inducible expression systems for modulating the expression of target genes in eukaryotic cells and non-human animalsSHEN YU·Filed 2004·Application pending·0 cites
- 3454US2010115635A1Methods for Assessing the Delivery of Exogenous AgentsABBOTT LAB·Filed 2009·Application pending·0 cites
- 3553US2025129096A1Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancerBOEHRINGER INGELHEIM INTL GMBH CORP·Filed 2022·Application pending·0 cites
- 3652US2025145608A1Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenesBOEHRINGER INGELHEIM INTL GMBH CORP·Filed 2022·Application pending·0 cites
- 3752US2006293229A1Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors thereforFESIK STEPHEN W·Filed 2005·Application pending·0 cites
- 3851US2024262822A1Wdr5 inhibitors and modulatorsUNIV VANDERBILT·Filed 2022·Application pending·0 cites
- 3948US7226992B1Mutant Bcl-2 proteins and uses thereofABBOTT LAB·Filed 2000·Granted Jun 5, 2007·0 cites·1 claims
- 4047US2003124673A1Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors thereforFiled 2002·Application pending·0 cites
- 4147US2010251392A1Methods for assessing the delivery of exogenous agentsABBOTT LAB·Filed 2008·Application pending·0 cites
- 4246US12398097B2WDR5-MYC inhibitorsUNIV VANDERBILT·Filed 2020·Granted Aug 26, 2025·0 cites·18 claims
- 4345US2023026466A1Wdr5 inhibitors and modulatorsUNIV VANDERBILT·Filed 2020·Application pending·0 cites
- 4443US2004180848A1Method of killing cancer cellsFiled 2004·Application pending·0 cites
- 4540US2004180844A1Method of killing cancer cellsFiled 2003·Application pending·0 cites
- 4638US11318137B2Quinazoline compounds as modulators of Ras signalingUNIV VANDERBILT·Filed 2017·Granted May 3, 2022·0 cites·41 claims
- 4736US9949965B2Tricyclic indole Mcl-1 inhibitors and uses thereofUNIV VANDERBILT·Filed 2015·Granted Apr 24, 2018·0 cites·19 claims
- 4836US2002055631A1N-acylsulfonamide apoptosis promotersFiled 2001·Application pending·0 cites
- 4935US2002037529A1Use of 13C nuclear magnetic resonance to detect binding to target moleculesFiled 2001·Application pending·0 cites
- 5029US2001004528A1Use of 13c nuclear magnetic resonance to detect binding to target moleculesFiled 1999·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stephen W. Fesik files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →